AtriCure (ATRC) Q1 2024: Open Ablation Sales Up 16.5% as Innovation Offsets Competitive Pressure

2024-05-01 | By EarningsIQ Research

AtriCure delivered broad-based double-digit growth in Q1, led by open ablation and international expansion, while navigating new competitive trialing in appendage management. Margin improvement and R&D investment signal a focus on innovation-led differentiation as the LEAPS trial and product launches set up multi-year growth levers.

Summary

• Open Ablation Adoption Accelerates: Encompass Clamp uptake and procedural efficiency drove segment outperformance.
• Competitive Trialing in Appendage Management: New entrants are present, but AtriCure maintained robust growth and sees long-term market expansion.
• Innovation Pipeline and Clinical Evidence: Upcoming launches and LEAPS trial position ATRC for sustained leadership and expanded indications.

Business Overview

AtriCure develops, manufactures, and sells medical devices for the treatment of atrial fibrillation (AFib), left atrial appendage management, and post-operative pain management. The company’s revenue primarily comes from its open ablation (devices for surgical ablation of AFib), appendage management (AtriClip product line for stroke prevention), minimally invasive ablation, and pain management (Cryosphere cryo-neuroblock technology) franchises. Its major segments are the U.S. and international cardiovascular surgery markets, with a growing presence in minimally invasive and hybrid procedures.

Performance Analysis

AtriCure posted 16% YoY revenue growth in Q1 2024, with performance driven by broad-based demand across open ablation (16.5% growth), appendage management (11% growth), minimally invasive ablation (27.8% growth), and pain management (15.1% growth). International revenue outpaced the U.S., growing 21.5%, reflecting the company’s ability to leverage product launches and guideline tailwinds abroad.

Gross margin improved to 74.7% as a result of favorable product and geographic mix and operational efficiencies. Operating expenses rose 16.1%, primarily due to a 29% increase in R&D spend, reflecting robust clinical trial enrollment (notably the LEAPS trial) and ongoing innovation. Adjusted EBITDA rose nearly 50% YoY, demonstrating early leverage on the back of higher sales and margin expansion. Cash burn was seasonally high in Q1 but is expected to reverse for the remainder of the year.

• Open Ablation Outperformance: Encompass Clamp adoption drove strong growth, now in use at over 450 accounts, with significant runway remaining.
• Appendage Management Mixed: Open products grew over 15%, offsetting softness in minimally invasive (MIS) and Lariat, which now contribute less to growth.
• Minimally Invasive and International: Hybrid AF therapy and new product launches drove outsized growth, especially OUS, where penetration remains low but accelerating.

Product mix and innovation are sustaining growth even as competitive trialing intensifies, and management’s guidance implies continued confidence in multi-segment momentum.

Executive Commentary

Strategic Positioning

1. Open Ablation Leadership and Encompass Clamp Penetration

The Encompass Clamp, open ablation device, is now used in under half of U.S. open ablation revenue, with adoption expanding across 450+ accounts. Management sees significant runway both in new accounts and increased utilization within existing ones. Efficiency gains and clinical validation are driving procedural preference, with a European launch expected to add momentum in late 2024.

2. Defending and Growing Appendage Management

Competitive trialing is active in appendage management, notably from Medtronic, but AtriCure’s open product line delivered 15.4% growth, supported by strong clinical evidence and deep surgeon relationships. The upcoming AtriClip Flex Mini launch and the LEAPS trial are positioned to expand the addressable market and further differentiate AtriCure’s offering, especially as global guidelines increasingly mandate appendage management.

3. Innovation Pipeline and Market Expansion

Multiple product launches are slated for 2024, including Cryosphere Plus and the AtriClip Flex Mini, each improving procedural efficiency or patient outcomes. The LEAPS trial, targeting 6,500 patients, seeks to demonstrate stroke reduction in a broader cardiac surgery population, potentially unlocking a multi-fold increase in the market size. Early-stage PFA (pulsed field ablation) integration across the portfolio is underway, aiming to keep AtriCure at the technological forefront.

4. International Growth and Guideline Tailwinds

International sales growth exceeded 21%, fueled by low penetration, favorable guideline changes, and new product launches. The LEAPS trial’s global footprint and recent European guideline updates are expected to accelerate adoption and reimbursement, particularly as the company establishes standard-of-care status in more markets.

5. Disciplined Capital Allocation for R&D and Profitability

R&D spend will remain high, at 19-20% of revenue in 2024, as management prioritizes innovation and clinical evidence generation. SG&A growth is moderating, enabling operating leverage and improved profitability, with adjusted EBITDA expected to rise in the second half of the year. The balance sheet remains robust to support these investments.

Key Considerations

AtriCure’s Q1 demonstrated resilience and momentum across its core franchises, but the quarter also surfaced important dynamics that will shape the company’s trajectory through 2024 and beyond.

Key Considerations:

• Competitive Trialing Is Here to Stay: Medtronic’s presence in appendage management is increasing, but trialing is not yet causing material share loss; rather, it is stimulating clinical conversations and therapy awareness.
• LEAPS Trial Is a Market Expander: If successful, LEAPS could drive a step-change in global appendage management adoption, with AtriCure’s product as the exclusive device in the trial.
• Product Launches Drive Pipeline Visibility: Encompass Clamp, Cryosphere Plus, and AtriClip Flex Mini launches are expected to sustain growth and margin expansion through improved efficiency and differentiation.
• International Opportunity Remains Vast: Penetration in global markets is under 10%, with recent guideline changes and trial expansion likely to accelerate uptake and reimbursement.
• R&D Investment Balances Profitability: Management is committed to high R&D spend to protect leadership and drive future growth, while leveraging SG&A for incremental margin improvement.

Risks

Competitive intensity is rising, especially in the U.S. appendage management market, as major players trial new devices and seek share. LEAPS trial results are critical—failure to demonstrate benefit could limit market expansion. International reimbursement and adoption remain sensitive to clinical evidence and local policy changes. High R&D spend may pressure near-term profitability if top-line growth slows or product launches underperform. Regulatory delays or adverse clinical outcomes could also disrupt the innovation pipeline.

Forward Outlook

For Q2 2024, AtriCure guided to:

• Sequential revenue growth in the mid- to upper-single digits, consistent with historical seasonality.
• Continued margin performance in line with 2023, with possible fluctuations from product and geographic mix.

For full-year 2024, management maintained guidance:

• Revenue of $459 to $466 million, representing 15-17% growth.
• Adjusted EBITDA of $26 to $29 million, with improvement weighted to the back half.

Management highlighted stable procedure trends, robust international momentum, and the impact of new product launches as key drivers for the remainder of the year.

• LEAPS enrollment pacing ahead, with full enrollment expected by mid-2025.
• Multiple product launches, notably in open ablation and pain management, will contribute incrementally.

Takeaways

AtriCure’s Q1 confirms its ability to grow through innovation, even as competition intensifies and product trialing increases. The company’s focus on clinical evidence, new product launches, and international expansion supports a durable growth narrative.

• Innovation-Led Growth: Encompass Clamp and Cryosphere launches are driving adoption and efficiency, supporting both top-line and margin expansion.
• Market Expansion Hinges on Clinical Evidence: LEAPS trial and evolving guidelines are pivotal for unlocking new patient populations, especially outside the U.S.
• Investors Should Watch Competitive Dynamics: Continued monitoring of share trends in appendage management, LEAPS trial progress, and execution on new product launches will be key for future quarters.

Conclusion

AtriCure’s Q1 2024 results reinforce its leadership in the surgical AFib and appendage management markets, with innovation and clinical investment driving growth despite competitive headwinds. The company’s execution on new product launches and the LEAPS trial will be critical to sustaining its trajectory and expanding its addressable market.

Industry Read-Through

This quarter’s results highlight the accelerating adoption of innovative surgical and hybrid AFib solutions, especially as clinical evidence and guideline changes reshape standard of care. Competitor trialing is a leading indicator for market expansion, not just share shifts, suggesting other device makers may also benefit from increased therapy awareness. International markets remain underpenetrated, with reimbursement and clinical trial alignment increasingly central to growth. Companies investing in evidence generation and procedural efficiency are best positioned to capture share as the market globalizes and competition intensifies.

ATRC Healthcare Medical Devices Cardiac Surgery Innovation Clinical Trials Appendage Management Product Launches